We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license research and collaborat... Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single in-office intravitreal IVT injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust sustained treatment response reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor VEGF injections. Show more
REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for...
REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for...
- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD...
REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.3 | -2.96735905045 | 10.11 | 10.84 | 9.5 | 404447 | 10.29729159 | CS |
4 | -2.2 | -18.3180682764 | 12.01 | 12.24 | 8.76 | 337896 | 10.1477791 | CS |
12 | -11.99 | -55 | 21.8 | 22.4 | 8.76 | 1011952 | 17.22231065 | CS |
26 | 0.55 | 5.93952483801 | 9.26 | 29.8 | 7.4 | 1229730 | 17.34697501 | CS |
52 | 1.61 | 19.6341463415 | 8.2 | 29.8 | 7.4 | 802618 | 16.9714361 | CS |
156 | -28.19 | -74.1842105263 | 38 | 40.1 | 5.31 | 1071520 | 19.14120198 | CS |
260 | -55.79 | -85.0457317073 | 65.6 | 269.8 | 5.31 | 1189213 | 61.59480684 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions